Testosterone After 40: What the Research Actually Shows About Optimization

By Deep Trivedi, MD | Atlas Lifespan

Men’s Health · June 2026

Testosterone levels in men decline gradually beginning around age 30, dropping roughly one to two percent per year on average. By the time a man reaches his mid-40s or 50s, that cumulative decline has often crossed a threshold where it begins to affect how he feels, functions, and performs. Low energy, declining muscle mass, increasing body fat, reduced libido, difficulty concentrating, and shifts in mood are the most commo presentations. Most men are told these are simply signs of getting older.

That framing is incomplete. The decline is real. Its consequences are not inevitable.

Testosterone replacement therapy (TRT), when properly evaluated, prescribed, and monitored, has a wellestablished body of evidence behind it. The conversation about men’s hormonal health has historically been oversimplified in both directions: either dismissed as unnecessary or reduced to libido and gym performance. The actual biology is more interesting and more relevant than either of those framings.

What Testosterone Actually Controls

Testosterone is not primarily a sex hormone. That framing undersells its function in the body considerably. It is a systemic anabolic hormone that affects nearly every tissue type.

Testosterone is essential for building and maintaining muscle mass and bone density. It governs fat distribution, particularly the accumulation of visceral fat around the organs. It regulates red blood cell production, mood, cognitive function, energy metabolism, and cardiovascular health. It plays a direct role in insulin sensitivity and is closely tied to metabolic function at the cellular level.

When testosterone falls below the range a given individual needs to function well, the effects are broad. Muscle is harder to build and easier to lose. Visceral fat accumulates, which worsens insulin resistance, which drives further hormonal dysfunction. Bone density declines. Energy drops, exercise recovery slows, and sleep quality often deteriorates. Mood instability, low motivation, and depression are documented and recognized consequences of hypogonadism that resolve with appropriate treatment.

The clinical definition of hypogonadism involves testosterone levels below a threshold (typically below 300 ng/dL on a morning measurement) in combination with symptoms. But the threshold alone does not tell the complete story. A man with a total testosterone of 310 ng/dL but severely reduced free testosterone (the biologically active fraction not bound to proteins) may be profoundly symptomatic. A man with high sex hormone binding globulin (SHBG) may have a total testosterone that appears acceptable while having almost no free testosterone available to his tissues. Reading the labs correctly requires more than one number.

Reading the Labs Correctly

A complete evaluation of male hormonal status requires a full panel, not a single total testosterone reading. The assessment we use at Atlas Lifespan includes:

Total testosterone, drawn in the morning when levels peak. Free testosterone, either measured directly or calculated, which reflects what is actually available to tissues. SHBG, because elevated SHBG binds testosterone in the blood and reduces free levels significantly. LH and FSH, the pituitary hormones that signal the testes to produce testosterone, which distinguish between primary hypogonadism (testicular failure) and secondary hypogonadism (a signaling problem upstream in the brain). Estradiol, because testosterone converts to estrogen through the aromatase enzyme, and both high and low estradiol cause problems in men. A complete blood count, because testosterone stimulates red blood cell production and hematocrit must be monitored. PSA as a baseline before starting therapy.

Treating low testosterone without this full picture is practicing with incomplete information. Treating it without ongoing monitoring introduces risk that is entirely avoidable with standard follow-up

What the Clinical Evidence Shows

The evidence for testosterone replacement therapy in men with documented hypogonadism is substantial and has strengthened considerably in recent years.

Muscle mass and physical function. A landmark study by Bhasin et al. published in the New England Journal of Medicine (1996) established that testosterone produces dose dependent increases in muscle mass and strength. The Testosterone Trials (TTrials), a coordinated series of NIH-funded randomized controlled trials published in the New England Journal of Medicine (Snyder et al., 2016), enrolled 790 men aged 65 and older with confirmed low testosterone. The trials demonstrated improvements in sexual function, increased bone mineral density, corrected anemia, and measurable improvements in walking endurance and physical capacity.

Bone density. Testosterone deficiency accelerates bone loss in men, a problem that is significantly underrecognized clinically. The TTrials bone sub-study found that testosterone therapy produced significant increases in volumetric bone mineral density at the spine and hip compared to placebo. This matters: osteoporosis in men carries the same fracture risk and the same consequences as in women, and it rarely gets the same clinical attention.

Metabolic health. A systematic review published in the European Journal of Endocrinology (Corona et al., 2016) analyzed data across multiple trials and found that TRT reduced fat mass, increased lean body mass, and improved insulin sensitivity and fasting glucose in hypogonadal men with metabolic dysfunction. For men with concurrent metabolic syndrome and low testosterone, the two conditions feed each other. Visceral fat drives aromatase activity, converting testosterone to estrogen and lowering testosterone further. Treating the hormonal deficiency is part of breaking that cycle.

Mood and cognition. Depression and low mood are recognized features of hypogonadism and are listed as such in the Endocrine Society clinical practice guidelines (Bhasin et al., J Clin Endocrinol Metab, 2018). The TTrials mood sub-study found statistically significant improvements in depressive symptoms in men on testosterone compared to placebo. Several observational studies have also found associations between low testosterone and accelerated cognitive decline in aging men.

The Cardiovascular Question, Answered

For years, the cardiovascular safety of TRT was the central unresolved concern in men’s hormonal health. A 2010 trial published in the New England Journal of Medicine was halted early due to an apparent signal of increased cardiovascular events in a small group of older men on testosterone, and the concern persisted even as the study was criticized for its design and its early termination.

The TRAVERSE trial, published in the New England Journal of Medicine in 2023 by Lincoff et al., was designed specifically to answer this question at scale. It enrolled more than 5,200 men between the ages of 45 and 80, all with confirmed hypogonadism and either existing cardiovascular disease or elevated cardiovascular risk. Participants were followed for a median of nearly 22 months. The result: testosterone replacement therapy was non-inferior to placebo for major adverse cardiovascular events, including heart attack and stroke. The fear that had shaped clinical practice and guidelines for more than a decade did not hold up under properly powered, prospective study.

TRAVERSE did find a modest increase in non-fatal atrial fibrillation in the testosterone group, and a small increase in pulmonary embolism. These findings reinforce the importance of appropriate patient selection and monitoring. TRT is not appropriate for men with a recent cardiovascular event, severe uncontrolled heart failure, or a clotting history without careful evaluation. But for appropriately selected men without those contraindications, the cardiovascular safety profile of TRT is now substantially clearer than it was before TRAVERSE.

Delivery Methods and Ongoing Monitoring

TRT is available in several delivery forms, and the right choice depends on a patient’s lifestyle, physiology, and how their body responds over time. Some methods produce steadier daily hormone levels; others allow for more frequent adjustment. There are meaningful tradeoffs between convenience, flexibility, and how the body absorbs and responds to each approach. Selecting the right delivery method is one of the decisions we work through with each patient individually at Atlas Lifespan.

Ongoing monitoring is not optional. TRT affects multiple systems in the body, and levels, blood markers, and other indicators need to be checked on a structured schedule after starting. Dosing is adjusted based on how you respond. This is not a prescription-and-goodbye situation. The patients who do best are those who treat it as an ongoing conversation with their physician, not a one-time transaction.

Fertility is an important consideration before starting. TRT suppresses the signals that drive natural testosterone production and sperm generation. Men who want to preserve fertility have options, but that conversation needs to happen before treatment begins, not after.

What Optimization Actually Looks Like

At Atlas Lifespan, every TRT evaluation begins with a complete hormonal and metabolic panel, a thorough clinical history, and an honest conversation about goals, expectations, and what the evidence actually supports. TRT works best as part of a broader strategy that includes resistance training, adequate protein, quality sleep, and metabolic management. The men who see the most meaningful improvements are those who treat hormone optimization as one component of how they are rebuilding their health, not a standalone intervention.

For men with documented hypogonadism and symptoms that are affecting their quality of life and long-term health trajectory, the evidence for TRT is solid. The conversation starts with a complete look at the labs, a clear explanation of options, and realistic expectations. That is the standard of care this should have always had.

If you want to understand your hormonal status and whether TRT belongs in your plan, schedule a
consultation at atlaslifespan.com.

Frequently Asked Questions About Testosterone Therapy